Nykode Therapeutics AS (VACBF)
OTCMKTS · Delayed Price · Currency is USD
0.3800
0.00 (0.00%)
At close: Feb 10, 2026

Nykode Therapeutics AS Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Feb '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
133886898412,6532,492
Market Cap Growth
74.02%-87.30%-18.07%-68.29%6.48%-
Enterprise Value
69-245286132,4662,473
Last Close Price
0.380.241.58---
PE Ratio
-----16.64
PS Ratio
18.119.5651.7393.1674.1811.55
PB Ratio
1.340.644.025.3613.6713.93
P/TBV Ratio
1.340.644.035.3613.6713.93
P/FCF Ratio
----9341.3113.83
P/OCF Ratio
----2296.9113.82
EV/Sales Ratio
8.98-39.6267.9068.9411.46
EV/EBITDA Ratio
-----13.87
EV/EBIT Ratio
-----13.87
EV/FCF Ratio
-1.93---8682.6113.73
Debt / Equity Ratio
0.030.030.030.040.040.00
Debt / EBITDA Ratio
-----0.00
Debt / FCF Ratio
----25.250.00
Asset Turnover
0.050.050.060.040.141.64
Quick Ratio
17.1412.787.945.418.1217.36
Current Ratio
17.1412.878.045.448.1617.38
Return on Equity (ROE)
-9.10%-25.25%-21.42%-24.35%-5.05%145.07%
Return on Assets (ROA)
-12.08%-16.70%-16.90%-13.64%-2.72%84.59%
Return on Invested Capital (ROIC)
-71.49%-250.18%----
Return on Capital Employed (ROCE)
-26.00%-33.50%-31.00%-29.10%-4.60%82.20%
Earnings Yield
-8.27%-44.34%-5.10%-5.08%-0.36%6.01%
FCF Yield
-26.89%-58.58%-14.30%-2.78%0.01%7.23%
Dividend Yield
-36.55%----
Buyback Yield / Dilution
22.32%-8.66%-3.58%-1.32%3.31%-1.14%
Total Shareholder Return
22.32%27.89%-3.58%-1.32%3.31%-1.14%
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.